Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.

Anderson, Timothy S; Ayanian, John Z; Souza, Jeffrey; Landon, Bruce E

Anderson, Timothy S; Ayanian, John Z; Souza, Jeffrey; Landon, Bruce E.

Affiliation

Anderson TS; Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Ayanian JZ; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor.
Souza J; Editor, JAMA Health Forum.
Landon BE; Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

JAMA ; 326(16): 1627-1629, 2021 Oct 26.

Article in En | MEDLINE | ID: mdl-34499725

Subject(s)

Alzheimer Disease/drug therapy; Antibodies, Monoclonal, Humanized/therapeutic use; Cognitive Dysfunction/drug therapy; Early Termination of Clinical Trials; Medicare/statistics & numerical data; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized/adverse effects; Clinical Trials, Phase III as Topic; Contraindications, Drug; Drug Approval; Female; Humans; Insurance Claim Review/statistics & numerical data; Male; Middle Aged; Patient Selection; United States; United States Food and Drug Administration

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Medicare / Early Termination of Clinical Trials / Alzheimer Disease / Antibodies, Monoclonal, Humanized / Cognitive Dysfunction Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: JAMA Year: 2021 Document type: Article

Fulltext

XML

PubMed Links

Search on Google